Avaliação da microbiota intestinal e uso de probióticos na doença de Alzheimer
DOI:
https://doi.org/10.25118/2763-9037.2024.v14.1346Palavras-chave:
doença de Alzheimer, microbiota intestinal, probióticos, microbioma gastrointestinalResumo
Introdução: Doença de Alzheimer é uma doença decorrente de processo neurodegenerativo que se manifesta por perdas cognitivas, em particular da memória episódica e da aprendizagem. Por ser um transtorno neurocognitivo que afeta a memória, pensamento e comportamento, é a causa mais comum de demência e apresentam um impacto significativo nas atividades diárias, com alta morbidade e mortalidade. A microbiota intestinal desempenha um papel importante na regulação das funções e do comportamento cerebral, por meio do eixo microbiota-intestino-cérebro. Diversos estudos têm demonstrado uma correlação entre a desregulação da microbiota intestinal e doenças neurodegenerativas. Objetivo: Descrever e analisar o envolvimento da microbiota intestinal e a relação dos probióticos na Doença de Alzheimer. Metodologia: Foi realizada uma revisão integrativa da literatura e selecionados artigos publicados de revistas indexadas nas bases de dados Scientific Electronic Library Online (SCIELO), National Library of Medicine/NLM (MEDLINE) e National Library of Medicine/NLM (PUBMED). Resultados: Os estudos avaliados demonstraram uma relação positiva da microbiota intestinal no desenvolvimento ou progressão da Doença de Alzheimer e embora existam poucos ensaios clínicos avaliando o efeito do consumo de probióticos em humanos com Doença de Alzheimer, os resultados encontrados até o momento indicam que a suplementação com probióticos possuem contribuição benéficas, como uma diminuição do processo inflamatório e da progressão da doença em questão. Conclusão: A microbiota intestinal pode ser influenciada por probióticos em pacientes com Doença de Alzheimer, trazendo melhoras cognitivas e comportamentais, melhorando assim a qualidade de vida desses pacientes.
Downloads
Métricas
Referências
Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312-39. https://doi.org/10.1016/j.cell.2019.09.001 - PMID:31564456 PMCID:PMC6778042 DOI: https://doi.org/10.1016/j.cell.2019.09.001
Chandra S, Sisodia SS, Vassar RJ. The gut microbiome in Alzheimer's disease: what we know and what remains to be explored. Mol Neurodegener. 2023;18:9. https://doi.org/10.1186/s13024-023-00595-7 PMID:36721148 PMCID:PMC9889249 DOI: https://doi.org/10.1186/s13024-023-00595-7
Morley JE, Farr SA, Nguyen AD. Alzheimer disease. Clin Geriatr Med. 2018;34(4):591-601. https://doi.org/10.1016/j.cger.2018.06.006 - PMID:30336989 DOI: https://doi.org/10.1016/j.cger.2018.06.006
Araújo SRM, Cunha ER, Marques IL, Paixão SA, Dias AFG, Sousa PM, Soares NKP, Sousa MO, Lobato RM, Souza MTP. Doença de Alzheimer no Brasil: uma análise epidemiológica entre 2013 e 2022. Res Soc Dev. 2023;12(2):e29412240345. https://doi.org/10.1055/s-0043-1767827 DOI: https://doi.org/10.33448/rsd-v12i2.40345
Eratne D, Loi SM, Farrand S, Kelso W, Velakoulis D, Looi JC. Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis. Australas Psychiatry. 2018;26(4):347-57. https://doi.org/10.1177/1039856218762308 - PMID:29614878 DOI: https://doi.org/10.1177/1039856218762308
Melo SC, Champs APS, Goulart RF, Malta DC, Passos VMA. Dementias in Brazil: increasing burden in the 2000-2016 period. Estimates from the Global Burden of Disease Study 2016. Arq Neuropsiquiatr. 2020;78(12):762-71. https://doi.org/10.1590/0004-282x20200059 - PMID:33295419 DOI: https://doi.org/10.1590/0004-282x20200059
Paschalidis M, Konstantyner TCRO, Simon SS, Martins CB. Trends in mortality from Alzheimer's disease in Brazil, 2000-2019. Epidemiol Serv Saude. 2023;32(2):e2022886. https://doi.org/10.1590/s2237-96222023000200002 - PMID:37194750 - PMCID:PMC10194304 DOI: https://doi.org/10.1590/s2237-96222023000200002
Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33. https://doi.org/10.1038/s41572-021-00269-y PMID:33986301 - PMCID:PMC8574196 DOI: https://doi.org/10.1038/s41572-021-00269-y
Grabher BJ. Effects of Alzheimer disease on patients and their family. J Nucl Med Technol. 2018;46(4):335-40. https://doi.org/10.2967/jnmt.118.218057 - PMID:30139888 DOI: https://doi.org/10.2967/jnmt.118.218057
Faulin TDES, Estadella D. Alzheimer's disease and its relationship with the microbiota-gut-brain axis. Arq Gastroenterol. 2023;60(1):144-54. https://doi.org/10.1590/s0004-2803.202301000-17 PMID:37194773
Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci. 2018;12:49. https://doi.org/10.3389/fnins.2018.00049 - PMID:29467611 PMCID:PMC5808284 DOI: https://doi.org/10.3389/fnins.2018.00049
Megur A, Baltriukienė D, Bukelskienė V, Burokas A. The microbiota-gut-brain axis and Alzheimer's disease: neuroinflammation is to blame? Nutrients. 2020;13(1):37. https://doi.org/10.3390/nu13010037 - PMID:33374235 PMCID:PMC7824474 DOI: https://doi.org/10.3390/nu13010037
Hung CC, Chang CC, Huang CW, Nouchi R, Cheng CH. Gut microbiota in patients with Alzheimer's disease spectrum: a systematic review and meta-analysis. Aging (Albany NY).
;14(1):477-96. https://doi.org/10.18632/aging.203826 -PMID:35027502 - PMCID:PMC8791218 DOI: https://doi.org/10.18632/aging.203826
Liu S, Gao J, Zhu M, Liu K, Zhang HL. Gut microbiota and dysbiosis in Alzheimer's disease: implications for pathogenesis and treatment. Mol Neurobiol. 2020;57(12):5026-43. https://doi.org/10.1007/s12035-020-02073-3 - PMID:32829453 PMCID:PMC7541367 DOI: https://doi.org/10.1007/s12035-020-02073-3
Xu C, Zhu H, Qiu P. Aging progression of human gut microbiota. BMC Microbiol. 2019;19:236. https://doi.org/10.1186/s12866-019-1616-2 - PMID:31660868 - PMCID:PMC6819604 DOI: https://doi.org/10.1186/s12866-019-1616-2
Pellegrini C, Fornai M, D'Antongiovanni V, Antonioli L, Bernardini N, Derkinderen P. The intestinal barrier in disorders of the central nervous system. Lancet Gastroenterol Hepatol. 2023;8(1):66-80. https://doi.org/10.1016/s2468-1253(22)00241-2 - PMID:36334596 DOI: https://doi.org/10.1016/S2468-1253(22)00241-2
Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, Chang EB, Tanzi RE, Sisodia SS. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci Rep. 2016;6:30028. https://doi.org/10.1038/srep30028 - PMID:27443609 PMCID:PMC4956742 DOI: https://doi.org/10.1038/srep30028
Leblhuber F, Steiner K, Schuetz B, Fuchs D. Commentary: does severity of Alzheimer's disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front Neurol. 2019;10:667. https://doi.org/10.3389/fneur.2019.00667 PMID:31333558 - PMCID:PMC6624731 DOI: https://doi.org/10.3389/fneur.2019.00667
Sichetti M, De Marco S, Pagiotti R, Traina G, Pietrella D. Anti-inflammatory effect of multistrain probiotic formulation (L. rhamnosus, B. lactis, and B. longum). Nutrition. 2018;53:95-102. https://doi.org/10.1016/j.nut.2018.02.005 - PMID:29674267 DOI: https://doi.org/10.1016/j.nut.2018.02.005
Zou X, Zou G, Zou X, Wang K, Chen Z. Gut microbiota and its metabolites in Alzheimer's disease: from pathogenesis to treatment. PeerJ. 2024;12:e17061. https://doi.org/10.7717/peerj.17061 - PMID:38495755 - PMCID:PMC10944166 DOI: https://doi.org/10.7717/peerj.17061
Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, Hamidi GA, Salami M. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2016;8:256. https://doi.org/10.3389/fnagi.2016.00256 - PMID:27891089 PMCID:PMC5105117 DOI: https://doi.org/10.3389/fnagi.2016.00256
Ton AMM, Campagnaro BP, Alves GA, Aires R, Côco LZ, Arpini CM, Guerra e Oliveira T, Campos-Toimil M, Meyrelles SS, Pereira TMC, Vasquez EC. Oxidative stress and dementia in Alzheimer's patients: effects of synbiotic supplementation. Oxid Med Cell Longev. 2020;2020:2638703. https://doi.org/10.1155/2020/2638703 - PMID:32411323 PMCID:PMC7201593 DOI: https://doi.org/10.1155/2020/2638703
Arora K, Green M, Prakash S. The microbiome and Alzheimer's disease: potential and limitations of prebiotic, synbiotic, and probiotic formulations. Front Bioeng Biotechnol. 2020;8:537847. https://doi.org/10.3389/fbioe.2020.537847 - PMID:33384986 PMCID:PMC7771210 DOI: https://doi.org/10.3389/fbioe.2020.537847
Frausto DM, Forsyth CB, Keshavarzian A, Voigt RM. Dietary regulation of gut-brain axis in Alzheimer's disease: importance of microbiota metabolites. Front Neurosci. 2021;15:736814. https://doi.org/10.3389/fnins.2021.736814 - PMID:34867153 - PMCID:PMC8639879 DOI: https://doi.org/10.3389/fnins.2021.736814
Krüger JF, Hillesheim E, Pereira ACSN, Camargo CQ, Rabito EI. Probiotics for dementia: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2021;79(2):160-70. https://doi.org/10.1093/nutrit/nuaa037 - PMID:32556236 DOI: https://doi.org/10.1093/nutrit/nuaa037
Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. https://doi.org/10.3390/microorganisms7010014 PMID:30634578 - PMCID:PMC6351938 DOI: https://doi.org/10.3390/microorganisms7010014
Brandscheid C, Schuck F, Reinhardt S, Schäfer KH, Pietrzik CU, Grimm M, Hartmann T, Schwiertz A, Endres K. Altered gut microbiome composition and tryptic activity of the 5xFAD Alzheimer's mouse model. J Alzheimers Dis. 2017;56(2):775-88. https://doi.org/10.3233/jad-160926 - PMID:28035935 DOI: https://doi.org/10.3233/JAD-160926
Castillo-Álvarez F, Marzo-Sola ME. Role of intestinal microbiota in the development of multiple sclerosis. Neurologia (Engl Ed). 2017;32(3):175-84. https://doi.org/10.1016/j.nrleng.2015.07.010 DOI: https://doi.org/10.1016/j.nrleng.2015.07.010
McCombe PA, Lee JD, Woodruff TM, Henderson RD. The peripheral immune system and amyotrophic lateral sclerosis. Front Neurol. 2020;11:279. https://doi.org/10.3389/fneur.2020.00279 PMID:32373052 - PMCID:PMC7186478 DOI: https://doi.org/10.3389/fneur.2020.00279
Engen PA, Dodiya HB, Naqib A, Forsyth CB, Green SJ, Voigt RM, Kordower JH, Mutlu EA, Shannon KM, Keshavarzian A. The potential role of gut-derived inflammation in multiple system atrophy. J Parkinsons Dis. 2017;7(2):331-46. https://doi.org/10.3233/jpd-160991 - PMID:28234259 DOI: https://doi.org/10.3233/JPD-160991
Scheperjans F, Derkinderen P, Borghammer P. The gut and Parkinson's disease: hype or hope? J Parkinsons Dis. 2018;8(s1):S31-9. https://doi.org/10.3233/jpd-181477 PMID:30584161 PMCID:PMC6311363 DOI: https://doi.org/10.3233/JPD-181477
Hill JM, Clement C, Pogue AI, Bhattacharjee S, Zhao Y, Lukiw WJ. Pathogenic microbes, the microbiome, and Alzheimer's disease (AD). Front Aging Neurosci. 2014;6:127. https://doi.org/10.3389/fnagi.2014.00127 DOI: https://doi.org/10.3389/fnagi.2014.00127
Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer's disease. J Alzheimers Dis. 2017;58(1):1-15. https://doi.org/10.3233/jad-161141 - PMID:28372330 DOI: https://doi.org/10.3233/JAD-161141
Lin L, Zheng LJ, Zhang LJ. Neuroinflammation, gut microbiome, and Alzheimer's disease. Mol Neurobiol. 2018;55(11):8243-50. https://doi.org/10.1007/s12035-018-0983-2 - PMID:29524051 DOI: https://doi.org/10.1007/s12035-018-0983-2
Liu P, Wu L, Peng G, Han Y, Tang R, Ge J, Zhang L, Jia L, Yue S, Zhou K, Li L, Luo B, Wang B. Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain Behav Immun. 2019;80:633-43. https://doi.org/10.1016/j.bbi.2019.05.008 - PMID:31063846 DOI: https://doi.org/10.1016/j.bbi.2019.05.008
Faulin TDES, Estadella D. Alzheimer's disease and its relationship with the microbiota-gut-brain axis. Arq Gastroenterol. 2023;60(1):144-54. https://doi.org/10.1590/s0004-2803.202301000-17 - PMID:37194773 DOI: https://doi.org/10.1590/s0004-2803.202301000-17
Jäger R, Mohr AE, Carpenter KC, Kerksick CM, Purpura M, Moussa A, Townsend JR, Lamprecht M, West NP, Black K, Gleeson M, Pyne DB, Wells SD, Arent SM, Smith-Ryan AE, Kreider RB, Campbell BI, Bannock L, Scheiman J, Wissent CJ, Pane M, Kalman DS, Pugh JN, Ter Haar JA, Antonio J. International Society of Sports Nutrition position stand: probiotics. J Int Soc Sports Nutr. 2019;16(1):62. https://doi.org/10.1186/s12970-019-0329-0 PMID:31864419 - PMCID:PMC6925426 DOI: https://doi.org/10.1186/s12970-019-0329-0
Gualtieri P, Marchetti M, Cioccoloni G, De Lorenzo A, Romano L, Cammarano A, Colica C, Condò R, Di Renzo L. Psychobiotics regulate the anxiety symptoms in carriers of Allele A of IL-1β gene: a randomized, placebo-controlled clinical trial. Mediators Inflamm. 2020;2020:2346126. https://doi.org/10.1155/2020/2346126 - PMID:32377159 - PMCID:PMC7199572 DOI: https://doi.org/10.1155/2020/2346126
Emery DC, Shoemark DK, Batstone TE, Waterfall CM, Coghill JA, Cerajewska TL, Davies M, West NX, Allen SJ. 16S rRNA next generation sequencing analysis shows bacteria in Alzheimer's post-mortem brain. Front Aging Neurosci. 2017;9:195. https://doi.org/10.3389/fnagi.2017.00195 PMID:28676754 - PMCID:PMC5476743 DOI: https://doi.org/10.3389/fnagi.2017.00195
Kim CS, Cha L, Sim M, Jung S, Chun WY, Baik HW, Shin DM. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: a randomized, double-blind, placebo-controlled, multicenter trial. J Gerontol A Biol Sci Med Sci. 2021;76(1):32-40. https://doi.org/10.1093/gerona/glaa090 PMID:32300799 PMCID:PMC7861012 DOI: https://doi.org/10.1093/gerona/glaa090
Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, Ferrari C, Guerra UP, Paghera B, Muscio C, Bianchetti A, Volta GD, Turla M, Cotelli MS, Gennuso M, Prelle A, Zanetti O, Lussignoli G, Mirabile D, Bellandi D, Gentile S, Belotti G, Villani D, Harach T, Bolmont T, Padovani A, Boccardi M, Frisoni GB; INDIA-FBP Group. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60-8. https://doi.org/10.1016/j.neurobiolaging.2016.08.019 - PMID:27776263 DOI: https://doi.org/10.1016/j.neurobiolaging.2016.08.019
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2024 Janaína Carla Parizotto da Rosa, Isadora Goldbaum Calil Lopes, Amanda Letícia Rainieri, Renato Daniel Ramalho Cardoso, Paula Souza Lage
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria permite que o (s) autor (es) mantenha(m) seus direitos autorais sem restrições. Atribuição-NãoComercial 4.0 Internacional (CC BY-NC 4.0) - Debates em Psiquiatria é regida pela licença CC-BY-NC
